Advertisement

Author Guidelines

Revisions to these Guidelines

 

PLEASE NOTE THAT EMBO MOLECULAR MEDICINE NOW REQUIRES A COMPLETE AUTHOR CHECKLIST (RIGHT CLICK AND 'SAVE AS') TO BE SUBMITTED WITH ALL REVISED MANUSCRIPTS.

 

About EMBO Molecular Medicine

Editorial Policies

Manuscript Preparation

Submission

For Acceptance and Publication

Help and Contact

 

ABOUT EMBO MOLECULAR MEDICINE

Aims and Scope

EMBO Molecular Medicine is a peer-reviewed, online open access journal dedicated to a new research discipline at the interface between clinical research and basic biology. It offers clinicians and researchers in this area the opportunity to publish their best work in a broadly distributed and highly visible forum, thereby lending a strong impetus to this important and rapidly developing field and helping to forge new links between clinicians and molecular biologists. Studies based on model organisms also fall within the scope of the journal, provided that the results presented are evidently and directly relevant to human disease. 

The journal is one of four journals owned and run by EMBO and is editorially entirely independent of its publisher Wiley-Blackwell. For further details on our relationship to other EMBO publications, please see below.

EMBO Molecular Medicine publishes research papers as full-length Research Articles and short Reports. In addition, the journal publishes Editorials and Review articles in innovative formats that target a broad and non-specialized audience as well as Closeups and Correspondences.

Areas covered include, but are not limited to:

  • Aging
  • Cancer biology
  • Differentiation and development
  • Endocrinology and metabolic diseases
  • Genomics, transcriptomics, proteomics, metabolomics of disease
  • Gene therapy
  • Human genetics, epigenetics and genomics
  • Immunology and inflammation
  • Infectious diseases
  • Molecular diagnostics and imaging
  • Molecular pharmacology and drug discovery
  • Neurodegeneration, neurological diseases and myopathies
  • Pain and sensory defects
  • Stem cells and regenerative medicine
  • Systems medicine
  • Vascular and cardiovascular biology

Article Types

EMBO Molecular Medicine publishes the following article types:

Research Articles and Reports

Original research papers, reporting novel molecular research highly relevant to the understanding, prevention, treatment or cure of human diseases. Reports are concise manuscripts that highlight a specific finding, model or methodology with a high impact on the field of molecular medicine.

Reviews

A broad and scholarly overview of a particular topic related to molecular medicine, noting the most recent developments in the field. They are supplemented with explanations for non-specialist readers and online links to relevant sources of additional information.

Bridge the Gap

These articles will help both basic and clinical researchers to better understand each other's perspectives and define common goals. Authors are encouraged to suggest new strategies and avenues of investigation that may fill the gaps they perceive as existing between the discovery of a biological mechanism and the application of the resultant concepts to the better understanding of a specific disease, its diagnosis, prevention or treatment. Alternatively, from a clinical perspective, authors might highlight disease phenotypes they consider to be poorly understood in molecular terms and suggest lines of research that would lead to such understanding.

Closeup articles

These articles are short commentaries commissioned on specific articles, discussing the advance and broader implications of the respective study or studies.

Editorials and Perspectives

These are opinion pieces that focus on important issues regarding biomedical research, its community and human health in general. Editorials are written by our editors, whereas Perspectives are invited by the journal editors.

Correspondences

A Correspondence is a flexible format that may include anything of interest to the journal's readers, from policy debates to announcements to 'matters arising' from research papers published in EMBO Molecular Medicine (see below for further information).

EDITORIAL POLICIES

Submission of a manuscript implies that it reports unpublished work and that neither itself, nor parts of it, have been published or are under consideration for publication elsewhere. By submitting a manuscript to EMBO Molecular Medicine, the authors guarantee that they have the appropriate authority from their employers and/or funding agencies to publish the work. Any related work under consideration, review, and revision or accepted for publication elsewhere should accompany the submission if they are relevant to its scientific assessment.

EMBO Molecular Medicine reserves the right not to publish material that has already been pre-published (either in electronic or other media). EMBO Molecular Medicine does allow prior publication on recognized community preprint servers (e.g. arXiv) for review by other scientists in the field before formal submission to the journal. The details of the preprint server concerned and any accession numbers must be included in the cover letter accompanying submission of the manuscript.

Authorship Guidelines

Submission of a paper implies that all authors have seen and approved the manuscript and its contents, and that they are aware of the responsibilities connected to authorship. Signatures from all the authors are not required; it is the corresponding author's responsibility to obtain agreement from all authors supporting the submission. All authors will be notified upon receipt of a new manuscript and upon acceptance of a manuscript, but the editorial office corresponds only with the Corresponding Author, whose responsibility it is to communicate with all other authors. The nature of every author's contribution must be specified in the manuscript under the heading "Author Contributions".

Our authorship policies conform to international standards (see, for example, http://www.icmje.org/ethical_1author.html).

We encourage the submission of a completed author checklist (right click to download) at submission (which covers animal welfare, human subjects, data deposition and ethics), and will require it to be filled and returned to the editorial office at revision, either via the online submission system (upload as a supplementary file) or by email (contact@embomolmed.org).

Use of living organisms and animal welfare

For studies reporting experiments on live vertebrates and/or higher invertebrates, the corresponding author must confirm that all experiments were performed in accordance with relevant guidelines and regulations. The manuscript must include a statement in the Materials and Methods identifying the institutional and/or licensing committee approving the experiments. The editors reserve the right to consult with board members or external experts and reject manuscripts that contain animal experiments that do not conform to NIH or MRC guidelines for animal welfare. For further information see: http://grants.nih.gov/grants/olaw/olaw.htm; http://www.mrc.ac.uk/Ourresearch/Ethicsresearchguidance/Useofanimals/index.htm.

We encourage authors to follow the ARRIVE guidelines (PLoS Biol. 8(6), e1000412, 2010) for reporting studies involving animals. Please see the following website for details: http://www.equator-network.org/reporting-guidelines/improving-bioscience-research-reporting-the-arrive-guidelines-for-reporting-animal-research/

Right click to download and complete the author checklist here.

Human Subjects

For experiments involving human subjects the corresponding author must identify the committee approving the experiments and include a statement that informed consent was obtained from all subjects and that the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Editors or referees may request further documentation confirming that this is the case. 

Any restrictions on the availability or on the use of human data or samples should be clearly specified in the manuscript. Any restrictions that may detract from the overall impact of a study or undermine its reproducibility will be taken into account in the editorial decision. 

For clinical trials reporting, the authors should fill out a CONSORT flow diagram and submit it as supplementary information. We also encourage authors to follow the CONSORT reporting guidelines http://www.consort-statement.org. Please see the EQUATOR website for details. Clinical trials should also be registered as recommended by the International Committee of Medical Journal Editors, and the trial registration number should be provided.

Reporting Guidelines

Authors are encouraged to follow the EQUATOR Network reporting guidelines for the following:

Type of Study Guidelines
Animal research ARRIVE
Parallel group randomized trials CONSORT
Conensus-based Clinical Case Reporting CARE
Prognostic marker studies REMARK
Diagnostic Accuracy STARD
Meta-analysis of observational studies MOOSE
Systematic reviews and meta-analysis PRISMA
Observational studies STROBE
Genetic association studies STREGA
Statistical analyses and methods STAMPL
Microarray/deep sequencing studies MIAME
Studies using biospecimens BRISQ

Right click to download and complete the author checklist here.

Biosecurity

On occasion, submitted papers may contain aspects that raise concerns about possible dual use of the reported research. Any such potential biosecurity implications should be explicitly described by the authors in their cover letter at submission. Referees should discuss any such concerns in direct correspondence with the editors. We encourage authors and referees to consult the definitions and recommendations formulated by the National Science Advisory Board for Biosecurity (NSABB) regarding the oversight of dual use life sciences research (http://oba.od.nih.gov/biosecurity/biosecurity_documents.html) and the list of select agents and toxins issued by APHIS/CDC (http://www.selectagents.gov/).

The threat posed by the potential abuse of certain experimental data or material for bioweapons, terrorist or other criminal activities may require that editors balance the risks and benefits of publication. The ultimate decision whether to publish is the prerogative of the editors after consultation with experts in biosafety, biosecurity, and public and environmental health.

Right click to download and complete the author checklist here.

Availability of published material and data

A condition of publication in all EMBO publications is that authors are required to make available to colleagues any of the biological material and reagents that were originally reported in the published research and that are not available from commercial sources. Material Transfer Agreements (MTA) should not pose undue qualifications and/or restrictions on the use of such materials (see also below). Materials should be shared with non-commercial users on a not-for-profit basis, although reasonable costs for their production, storage and distribution may be charged.

MTAs that limit the reuse of material, reagents, software or data should be submitted together with the original submission and may be published as part of the Expanded View. Datasets obtained by experimentation, computation or data mining should be made freely available, without restriction. This holds without exception to data that are central and integral to the findings reported in the paper and it is strongly recommended for any remaining associated data.

Software should be described in sufficient detail to allow reproduction of the underlying algorithms by others. This may be achieved by providing the appropriate narrative or mathematical description, pseudocode and, possibly but not obligatorily, the source code. If a specific implementation is the focus of the study, it is strongly recommended that non-commercial users be granted free access to this implementation.

Any restrictions that may detract from the overall impact of a study and that are central to the findings reported will be taken into account in the final editorial decision. Readers who encounter persistent refusal by the authors to comply with these policies should contact the Chief Editor of the journal. Conversely, authors who have legal, ethical or security concerns about the possible abuse or misuse of the material requested by a specific institution should also contact the editors, who may review the requests and consult with experts whether it is prudent to reject a specific sharing request.

In cases where editors are unable to resolve a complaint, the journal may refer the breach of publication rules to the funding and/or host institution of the author. The editors reserve the right to retract a paper persistently in breach of the journal's materials sharing policies or to publish a formal note of concern that specific materials are not available.

Conflicts of interest

In the interests of transparency and to help editors and reviewers assess any potential bias, EMBO Molecular Medicine requires authors of original research papers to declare any competing commercial interests in relation to the submitted work. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or indirectly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include but are not limited to patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication in this journal. It is difficult to specify a threshold at which a financial interest becomes significant, but as a practical guideline, we would suggest this to be any undeclared interest that could embarrass you were it to become publicly known. Referees and editors are also subject to Conflict of Interest regulations.

If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and to collectively list in the cover letter, in the manuscript (in the footnote, Conflict of Interest or Acknowledgments section), and in the online submission system ALL pertinent commercial and other relationships.

Scientific integrity

The editorial staff of EMBO Molecular Medicine is strongly committed to maintaining high standards of integrity of the published scientific record. The journal requests that authors take note of and adhere to guidelines established by the U.S. Department of Health and Human Services Office of Research Integrity (http://ori.dhhs.gov). The journal will investigate suspected instances of scientific fraud, inappropriate image manipulation, plagiarism, duplicate publication and other cases that violate research ethics. Depending on the outcome of these investigations, the journal may opt to publish errata or corrigenda, or, in cases of serious scientific misconduct, either to ask authors to retract their paper, or to impose retraction on them. In such cases, the authors' employers may also be contacted. As a matter of policy, the journal will collaborate with independent institutional investigations into misconduct and usually accept the outcome of such investigations.

An erratum is notification of an important error made by the journal, whereas a corrigendum is notification of an important error made by the author(s).

Refutations of articles published in EMBO Molecular Medicine can be considered for the Correspondence section of the journal. Such correspondence will almost always include data to support the arguments of the correspondent. The original authors of that article will be offered the opportunity to respond side-by-side with the correspondence. Both pieces will be peer reviewed at the discretion of the editor and acceptance depends on the strength of the arguments raised as well as the importance of the matter to a general readership. Publication of the correspondence does not automatically entail publication of a response of the authors of the challenged research paper.

After one round of correspondence, EMBO Molecular Medicine will consider the matter closed and will not publish further exchanges.

EMBO Molecular Medicine is a member of the Committee on Publication Ethics (COPE).

Data collection and presentation

Presented data must represent the findings in a fair and accurate manner. This includes appropriate statistical analysis and image processing. For further details, please refer to these guidelines.

The editors reserve the right to request original versions of figures and the source data that were used to assemble the figure from the authors of a paper under consideration, or of a paper already published in EMBO Molecular Medicine.

Originality & Plagiarism

The editors require that any information published in the journal represents a substantially novel contribution to the scientific record. Any manuscript submitted to EMBO Molecular Medicine should therefore not contain content that has been formally published in a peer reviewed journal or another formally citable manner, whether in print or electronic. This includes websites, blogs and the news media.

Subject to licensing restrictions, EMBO Molecular Medicine will consider for publication manuscripts based on information that has been previously discussed by the authors at scientific conferences in the form of posters, talks, abstract books, meeting reports or webcasts. Manuscripts may be posted prior to or at the time of submission on recognised non-peer reviewed pre-publication platforms dedicated to discussion among peers, including the preprint servers bioRXiv and arXiv, and Faculty1000 posters. The details of the preprint server concerned and any accession numbers must be included in the cover letter accompanying submission of the manuscript. EMBO Molecular Medicine will also consider manuscripts based on unpublished academic theses released in accordance with institutional rules.
 
Any text, data, material, images, ideas or quotes should be attributed to the original source, even if it is by the same authors. If necessary, authors should seek permission to use the material from the copyright holder in accordance to licensing stipulations. EMBO Molecular Medicine's policies on attribution follow the standards set by the Associated Press. It is at the discretion of the editors whether prior publication of such related material prevents subsequent publication in the journal.
 
Plagiarism includes both the theft or misappropriation of intellectual property and the substantial unattributed textual copying of another's work. EMBO Molecular Medicine uses CrossCheck, a multi-publisher initiative to screen submitted content for plagiarism, to detect overlapping and similar text (including self-plagiarism) prior to publication. To find out more about CrossCheck visit http://www.crossref.org/crosscheck.html.

Citation

Comprehensive and accurate citation of the relevant literature is essential. We require citation of the primary literature wherever appropriate. To enable this, we have removed any limits on the total number of references in the bibliography, and the reference list is no longer subject to manuscript length format requirements (for details, see below).

Embargo policy

The content of papers and any associated press releases is strictly embargoed until the official date of publication of a manuscript. Accepted contributions can be discussed with the media from one week before the publication date provided the journalist respects the embargo date. We will press release selected papers with summaries. Authors may arrange their own publicity, but must adhere to the embargo conditions and are encouraged to contact the editorial office. Further details can be provided by the editorial office. (contact@embomolmed.org).

Editorial process

All submissions are initially assessed by a dedicated Editor of the journal and may also be evaluated by an appropriate Senior Editor, Editorial Advisory Board member, or other external expert advisor. Only manuscripts judged by the editors to be potentially suitable for publication in EMBO Molecular Medicine are sent out for formal peer review, so that manuscripts with a low probability of success can be returned to the authors without delay. Manuscripts are generally reviewed by three appropriate experts selected by the editors. Based on their arguments and recommendations, the decision concerning publication, revision or rejection is taken, sometimes after further consultation with the referees, the editorial advisory board or indeed the authors. Revisions are invited only for manuscripts that have a high probability of acceptance after one major round of revision. Authors may appeal decisions if there is concrete evidence for a misunderstanding or mistake at the editorial or referee level. Appeals are evaluated in depth and without prejudice. 

Further information on the journal's peer review process can be found in our Guide for Referees

Transparent peer review process

EMBO Molecular Medicine makes the editorial process transparent for all accepted Research Articles and Reports, by publishing as an online supplementary document (the Peer Review Process File, PRPF) all correspondence between authors and the editorial office relevant to the decision process. This will include all referee comments directed to the authors, as well as the authors' point-by-point responses. Internal communications and informal consultations between editors, editorial advisors or referees will remain excluded from these documents. Importantly, referee anonymity will be strictly maintained. Authors have the possibility to opt out of the transparent process at any stage prior to publication.

To further facilitate transparency, EMBO Molecular Medicine has removed the "Confidential Comments" field from our referee reporting forms. This is to ensure that the authors receive all information pertinent to the decision made on a manuscript. Referees should be aware that all comments will be transmitted to the authors and the other referees. Should there be any issues with the manuscript, in particular concerns about ethical standards, data integrity, biosecurity, or conflicts of an academic or commercial nature that need to be communicated directly and confidentially to the editor, this can be done by email (contact@embomolmed.org). Please see the following editorial for more information on these policies: Transparency and accountability.

Transfer policies

EMBO Molecular Medicine is editorially independent of its publisher Wiley-Blackwell and of the other EMBO Scientific Publications.

Authors can choose to transfer manuscripts rejected from EMBO Molecular Medicine to any of the other three EMBO Publications (The EMBO Journal, EMBO reports, Molecular Systems Biology) by following the instructions appended to the editorial decision letter. Manuscripts transferred post-review will automatically include the referees' reports and identities, and the editors will aim to use these reports in arriving at a rapid decision. Editors may choose to seek additional advice from referees or editorial advisory board members in cases where this would enhance informed decision-making.

MANUSCRIPT PREPARATION

General guidelines for submission

The Editors reserve the right to return manuscripts that are not in accordance with the following instructions. However, manuscript will not be rejected out of hand for format reasons: while published manuscripts are expected to conform tightly to the following guidelines, this is not a requirement at first submission. Manuscripts must be written in clear and concise English and be intelligible to a broad readership. Prior to submission, authors may benefit from having their manuscript reviewed for clarity by colleagues and/or by using one of the many English language-editing services that are available.

Original research articles

Formats

EMBO Molecular Medicine publishes original research in two main formats: Articles and Reports

Articles

Manuscripts for primary research articles can be up to approximately 60,000 characters (including spaces) in length. This includes title page, abstract and figure legends, but excludes references, tables and Expanded View material. Should your manuscript exceed this length, some material can be presented as part of the Expanded View (see below). Please use 'Times' font at 10 or 12-point size for all text pages, 'Symbol' font for non-Latin characters, and 'Arial or Sans-serif' font for lettering on figures. 'Courier' font may be used for sequence data. Number each page at the bottom (Title page is 1). Articles should be divided into the following sections:

  • Title page
  • Abstract
  • Introduction
  • Results
  • Discussion
  • Materials and methods
  • Acknowledgements
  • Author Contributions
  • Conflict of Interest
  • The Paper Explained
  • For More Information
  • References
  • Figure legends
  • Figures
  • Tables
  • Expanded View (replaces Supporting Information)

Reports

Reports are short publications focusing on a particularly provocative and novel aspect of a study. Reports should have an Abstract phrased in terms that are comprehensible to readers outside the discipline. Results and Discussion sections can be combined. The remaining sections are organized as described above for Articles. The total character count (including spaces) for Reports, excluding the References, Material and Methods section, tables and Expanded View material, but including title page, abstract and figure legends, should not exceed 22,000 characters (the exact character count to be stated on the title page). Reports have, in principle, a maximum of 3 Figures. Manuscripts exceeding this limit at submission may be returned to the authors for amendment. Please consider including material as part of the Expanded View (see below) if your manuscript exceeds the above limitations.

Text and structure

Title page - The title should be short and informative, and should not contain any abbreviations (for example, Epithelial-Mesenchymal Transition should not be abbreviated to EMT). However, commonly used gene or protein acronyms are acceptable. The total length of the title should not exceed 175 characters (including spaces). Serial titles are not accepted. The full name of each author should be given and surnames underlined. Multiple first-authorships are acceptable and should be indicated. Numbers in superscript should be used to indicate the department, institution, city, and country for each author. Corresponding Authors should also indicate telephone and fax number as well as e-mail address. Any changes of address may also be given in numbered footnotes. It is possible to name more than one author as the correspondent of a published article, although we will by default address all correspondence to the single author listed as Corresponding Author upon submission. Please provide a running title of no more than 50 characters including spaces. Up to five keywords, which may or may not appear in the title, should be given in alphabetical order, below the abstract.

Abstract - This should be a single paragraph not exceeding 175 words. The Abstract should be comprehensible to readers before they have read the paper, and abbreviations should be avoided where possible (as for the title). Reference citations within the abstract are not permitted. The abstract should describe all key novel findings of the study.

Introduction - The Introduction should be succinct and without subheadings. It should provide only the necessary background information, rather than comprise a comprehensive review of the field. Citation of the primary literature is required where appropriate (see editorial policies).

Results - The Results section, and associated figures, tables and Expanded View Information, must accurately describe the findings of the study. Figure order should follow the text. Detailed methodological descriptions should be restricted to the Materials and Methods section. 'Data not shown' is not permitted (see below): all significant data should be displayed in the main figures or as part of the Expanded View.

Discussion - The Discussion should accurately interpret the results, but not be repetitive with the Results section. Authors are encouraged to discuss their work in the broader context. Related published data must be appropriately discussed and cited. Speculation is allowed but should be clearly labelled as such.

Materials and Methods - This section should contain sufficient detail so that all experimental procedures can be repeated by others, in conjunction with cited references. Reagents must be described in such a way as to allow readers to identify them unequivocally and/or reproduce them. For example, antibodies epitopes should be described and siRNA and other probe sequences must be provided. In cases where detailed methods cannot be described within the length limits of the article, additional Materials and Methods can be included as part of the Expanded View. This additional information should, however, not be of immediate importance for the understanding of the manuscript, and it is not permissible to move the entire Materials and Methods section into the online supplement.

Acknowledgements - These should be placed at the end of the text and not in footnotes. Personal acknowledgements should precede those of institutions or agencies. Grant numbers are permissible. Dedications are discouraged.

Author Contributions - EMBO Molecular Medicine requires a statement specifying the contributions of every author. Further details on authorship can be found here.

Conflict of Interest - EMBO Molecular Medicine requires a statement specifying whether or not the authors have a Conflict of Interest (see above for details). In the case of a Conflict of Interest, this must be specified.

The Paper Explained - EMBO Molecular Medicine articles are accompanied by a structured summary of the article to emphasize the major findings of the paper and their medical implications for the non-specialist reader. Please provide a summary accessible to non-specialists and specialists alike, highlighting the medical issue you are addressing (heading: PROBLEM), the results obtained (heading: RESULTS), and their clinical impact (heading: IMPACT). This may be edited to ensure that readers understand the significance and context of the research. Please refer to any of our published primary research articles for an example.

For More Information - There is space at the end of each article to list relevant web links for further consultation by our readers. Examples include patient associations, relevant databases, OMIM/proteins/genes links or author's websites.

References - As a matter of policy, EMBO Molecular Medicine requires the citation of primary literature (over review articles) wherever appropriate. Authors are responsible for the accuracy of the references. Authors are responsible for ensuring that the related literature is accurately and comprehensively discussed and cited. Review articles should only be cited for general background information, the proposal of certain concepts or similar purposes, whereas primary research articles should be preferentially be referenced to introduce the question being addressed or to support the conclusions and interpretations of the results. Articles in press can be cited with the explicit permission of the corresponding author of the study; the journal name has to be included and, where available, the Digital Object Identifier. Reference formatting information can be found here.

Figure legends - Figure legends should contain sufficient information to allow the reader to follow the data presented without referring back to the text, but should not be redundant with the Results section. Each figure must contain a heading, and each panel a subheading. General text applying to all subpanels should be placed before the subheadings. All symbols and abbreviations used in the figure must be defined, unless they are common abbreviations or have already been defined in the text. Experimental details should, where possible, be given in the Materials and Methods section, and not repeated in the figure legends. Legends should be limited to 350 words in length.

Unpublished Data

EMBO Molecular Medicine does not permit citation of "Data not shown". All data referred to in the paper should be displayed in the main or Expanded View figures. "Unpublished observations" may be referred to in exceptional cases, where these are data peripheral to the major message of the paper and are intended to form part of a future or separate study. Personal communications (Author name(s), personal communications) must be authorised in writing by those involved, and the authorisation sent to the editorial office at time of submission. Care should be taken that embargo policies are not contravened. References to manuscripts in preparation or submitted, but not yet accepted, should be cited in the text as (Author names(s), in preparation), and should not be included in the list of references. Copies of such manuscripts should be enclosed at submission for reviewing purposes where relevant, as should manuscripts in press, which should be cited in the reference list (see below).

Conventions and Abbreviations

In general, the journal follows conventions given in Scientific Style and Format: The CBE Manual for Authors, Editors and Publishers (1994) Cambridge University Press, Cambridge, UK, 6th edn. Please follow Chemical Abstracts and its indexes for chemical names. For guidance in the use of biochemical terminology follow the recommendations issued by the IUPAC-IUBMB Joint Commission on Biochemical Nomenclature. In general, genes and genotypes should be indicated in italics; proteins and phenotypes should not be italicized.

Authors should use approved gene and gene product nomenclature and apply the italicization and capitalization formatting as appropriate for each organism's standard nomenclature. Please consult the appropriate nomenclature databases for correct gene names and symbols. Some useful general resources are: Entrez Gene (http://www.ncbi.nlm.nih.gov/gene); UniProt (http://www.uniprot.org/).

Try to restrict the use of abbreviations to SI symbols (standard units of measurements) and those recommended by the International Union of Pure and Applied Chemistry (IUPAC). Abbreviations should be defined in brackets after their first mention in the text, not in a list of abbreviations. SI symbols and symbols of chemical elements may be used without definition in the body of the paper. Abbreviations of standard biochemical compounds, e.g. ATP, DNA, nucleotides in nucleic acids, and amino acids in proteins, need not be defined. Common language abbreviations, such as e.g. or i.e., should not be used.

OTHER ARTICLE TYPES

Review

Reviews provide the reader with the background to, and a broad overview of a particular topic related to molecular medicine, while noting the most recent developments in the field. They are supplemented with explanations for non-specialist readers, online links to relevant sources of additional information as well as a Pending Issues section. Reviews must be based on published data. The total character count for a Review, including spaces, figure legends and references, may not exceed 50,000 characters and the exact character count should be stated on the front page of the manuscript. We strongly encourage authors to include explanatory Figures and Tables. Our in-house graphics editor will aid in the preparation of the final figures for publication if a review is accepted. Reviews are usually commissioned but can also be submitted. All manuscripts submitted for this section will be peer-reviewed and may be extensively edited.

Bridge the Gap

Bridge the Gap articles will help both basic and clinical researchers to better understand each other's perspectives and define common goals. Authors are encouraged to suggest new strategies and avenues of investigation that may fill the gaps they perceive as existing between the discovery of a biological mechanism and the application of the resultant concepts to the better understanding of a specific disease, its diagnosis, prevention or treatment. Alternatively, from a clinical perspective, authors may highlight disease phenotypes that they consider to be poorly understood in molecular terms and suggest lines of research that would lead to such understanding. Bridge the Gap articles are supplemented with explanations for non-specialist readers and online links to relevant sources of additional information. The total character count, including spaces, figure legends and references, may not exceed 30,000 characters and the exact character count should be stated on the front page of the manuscript. We strongly encourage including explanatory figures, models and tables.

Bridge the Gap articles are usually commissioned but can also be submitted. All manuscripts submitted for this section will be peer-reviewed and may be extensively edited.

Closeup

Closeup articles are short, focused highlights of a specific development [often an original article(s) published in our journal or elsewhere] in our understanding of a clinically relevant issue. They are aimed at non-specialist readers and are supplemented with explanatory text and online links to relevant sources of additional information. The total character count for a Closeup, including spaces, figure legends and references, may not exceed 10,000 characters and the exact character count should be stated on the front page of the manuscript. The number of references should not exceed 10. We strongly encourage authors to include an explanatory figure. Closeups are usually commissioned by the Editors. We are also open to original un-invited submissions but would urge you to contact the Editorial Office beforehand. All manuscripts submitted for this section will be peer-reviewed and may be extensively edited.

Editorial and Perspective

Editorials and Perspectives are opinion pieces that focus on issues of high importance to biomedical research, the corresponding research communities and human health in general. These are short pieces of approximately 1000 words. Editorials are written by our editors, while Perspectives are invited by the journal editors. They are non peer-reviewed opinion pieces that focus on a particular scientific or sociopolitical topic pertinent to the Molecular Medicine community. They are intended to reflect primarily the views of the author(s) on the issue under review and authors are encouraged to put forward their own ideas and opinions.

Correspondence

A Correspondence is a flexible format that may include anything of interest to the journal's readers, from policy debates to announcements to 'matters arising' from research papers. A Correspondence may describe primary research data, but only one Figure and one Table are allowed. A Correspondence has no abstract and should be limited to 1000 words in principle. The number of references should not exceed 10 for either the Correspondence or its Reply. Expanded View material can in principle only be in the form of structured data or dataset files. Authors must submit a competing financial interests statement, which is included only if they declare that they have competing interests. In cases where a Correspondence is critical of a previous research paper, the authors are normally given the option of publishing a brief reply. Criticism of opinions or other secondary matter does not involve an automatic right of reply. Refutations and commentaries on previously published articles are always peer reviewed. Other types of Correspondence may be peer reviewed at the editors' discretion.

GENERAL FORMATTING GUIDELINES

Text

The Editorial Office will only accept text files in RTF or MS Word format. The final character count must be clearly indicated on the title page of the manuscript. Manuscripts that do not comply with the formatting guidelines, or exceed the length restrictions, may be returned to the authors for amendment. Please submit the full text (including figure legends, tables, and references) as a single MS Word or RTF file.

Figures

Figures and Expanded View figures should be presented in the order they are mentioned in the text. Figures should be labelled in consecutive Arabic numerals. The final size of figures will be between 82 mm and 172 mm wide on the printed page. Please bear this in mind when submitting your manuscript for review and allow for sufficient resolution at a suitable size.

Figures divided into parts should be labelled with an upper case, bold letter (Helvetica Font large enough to remain readable even if the figure is reduced upon publication). Figures with several parts should also be in proportion, with consistently sized lettering so that the whole figure can be reduced by the same amount to the smallest size at which the essential details are visible. Use Courier font for sequence data and Symbol font for any symbols.

All lettering should be done using standard fonts (Helvetica, Times, Symbol, Courier) and retained in a separate layer (if possible) so that the production team can adapt any labels to the Journal's style if necessary. All fonts used for labelling the figures should also be embedded in the final files if the software package offers this option.

Scale bars, rather than magnification factors, should be used, with the length of the bar defined in the legend rather than on the bar itself. In general, visual cues on the figure itself are preferred rather than verbal explanations (for example, 'broken line' or 'filled black triangles') in the legend. When preparing figures of microscopy images, please note that we strongly encourage the use of colours that are suitable for colour-blind readers: for example, the use of magenta/green is preferred over red/green for 2-channel images.

For publication, we use TIFF and EPS files in PC or Macintosh format, preferably from Photoshop or Illustrator software. We cannot accept Freehand, Canvas, CorelDRAW or MacDrawPro files. These files must be converted to postscript (eps) format. For any figures submitted in Photoshop or tiff format we require layered files to be sent whereby all text, arrows or additional attributes are placed on individual layers within the file. For line art/charts/graphs we prefer to work with Adobe Illustrator AI or EPS files. We can also accept high-resolution PDF files. All digitized images submitted with the final revision of the manuscript must be of high quality and have resolutions of at least 300 d.p.i. for colour, 600 d.p.i. for greyscale, 400 d.p.i. for photos, and 800 d.p.i. for line art.

EMBO Molecular Medicine does not have colour charges for figures, and authors are therefore welcome to submit full colour figures; however, as all articles published by EMBO Molecular Medicine are fully open access and therefore immediately freely available to read, download and share, there is an article publication charge to cover the cost of publishing. Details on the article publication charge can be found here.

Data Presentation

Figures must accurately reflect the results of the experiments. Appropriate controls, markers and scale bars should be included in all panels. Statistical tests must be clearly defined and appropriate to the data.

Image Processing
Images submitted with a manuscript for review should be minimally processed (for instance, to add arrows to a micrograph). Authors should retain their unprocessed data and metadata files, as editors may request them to aid in manuscript evaluation. If unprocessed data are unavailable, manuscript evaluation may be stalled until the issue is resolved.

A certain degree of image processing is acceptable for publication (and for some experiments, fields and techniques is unavoidable), but the final image must correctly represent the original data and conform to community standards. The guidelines below will aid in accurate data presentation at the image processing level; authors must also take care to exercise prudence during data acquisition, where misrepresentation must equally be avoided. Where appropriate, manuscripts should include extended Methods as part of the Expanded View that describe for each figure the pertinent instrument settings, acquisition conditions and processing changes, as described in this guide.

Authors should list all image acquisition tools and image processing software packages used. Authors should document key image-gathering settings and processing manipulations in the Methods.

Images gathered at different times or from different locations should not be combined into a single image, unless it is stated that the resultant image is a product of time-averaged data or a time-lapse sequence. If juxtaposing images is essential, the borders should be clearly demarcated in the figure and described in the legend.

The use of touch-up tools, such as cloning and healing tools in Photoshop, or any feature that deliberately obscures manipulations, is to be avoided.

Processing (such as changing brightness and contrast) is appropriate only when it is applied equally across the entire image and is applied equally to controls. Contrast should not be adjusted so that data disappear. Excessive manipulations, such as processing to emphasize one region in the image at the expense of others (for example, through the use of a biased choice of threshold settings), is inappropriate, as is emphasizing experimental data relative to the control.

When submitting revised final figures upon conditional acceptance, authors may be asked to submit original, unprocessed images.

Electrophoretic gels and blots
Positive and negative controls, as well as molecular size markers, should be included on each gel and blot. For previously characterized antibodies, a citation must be provided. For antibodies less well characterized in the system under study, a detailed characterization that demonstrates not only the specificity of the antibody, but also the range of reactivity of the reagent in the assay, should be published as part of the Expanded View.

The display of cropped gels and blots in the main paper is permitted if it improves the clarity and conciseness of the presentation. Cropped gels in the paper must retain all important bands, and space (several bandwidths) should be retained above and below the relevant band(s). Vertically sliced images that juxtapose lanes that were non-adjacent in the gel must have a clear separation or a black line delineating the boundary between the gels.

Quantitative comparisons between samples on different gels/blots are discouraged; if this is unavoidable, the figure legend must state that the samples derive from the same experiment and that gels/blots were processed in parallel. Loading controls must be run on the same blot.

High-contrast gels and blots are discouraged, as overexposure may mask additional bands. Authors should strive for exposures with gray backgrounds. Multiple exposures should be presented as part of the Expanded View if high contrast is unavoidable. Immunoblots should be surrounded by a black line to indicate the borders of the blot, if the background is faint.

For quantitative comparisons, appropriate reagents, controls and imaging methods with linear signal ranges should be used.

Microscopy
Authors should be prepared to supply the editors with original data on request, at the resolution collected, from which their images were generated. Cells from multiple fields should not be juxtaposed in a single field; instead multiple supporting fields of cells should be shown as part of the Expanded View.

Specific guidelines: Adjustments should be applied to the entire image. Threshold manipulation, expansion or contraction of signal ranges and the altering of high signals should be avoided. If 'Pseudo-colouring' and nonlinear adjustment (for example 'gamma changes') are used, this must be disclosed. Adjustments of individual colour channels are sometimes necessary on 'merged' images, but this should be noted in the figure legend.

We encourage inclusion of the following with the final revised version of the manuscript for publication.

In the Methods, specify the type of equipment (microscopes/objective lenses, cameras, detectors, filter model and batch number) and acquisition software used. Although we appreciate that there is some variation between instruments, equipment settings for critical measurements should also be listed.

An extended Methods section in the Expanded View (or part of a larger Methods section) titled 'equipment and settings' should list for each image: acquisition information, including time and space resolution data (xyzt and pixel dimensions); image bit depth; experimental conditions such as temperature and imaging medium; and fluorochromes (excitation and emission wavelengths or ranges, filters, dichroic beamsplitters, if any).

The display lookup table (LUT) and the quantitative map between the LUT and the bitmap should be provided, especially when rainbow pseudocolor is used. If the LUT is linear and covers the full range of the data, that should be stated.

Processing software should be named and manipulations indicated (such as type of deconvolution, three-dimensional reconstructions, surface and volume rendering, 'gamma changes', filtering, thresholding and projection).

Authors should state the measured resolution at which an image was acquired and any downstream processing or averaging that enhances the resolution of the image.

Statistical analysis
The description of all reported data that includes statistical testing must state the name of the statistical test used to generate error bars and P values, the number (n) of independent experiments underlying each data point (not replicate measures of one sample), and the actual P value for each test (not merely 'significant' or 'P < 0.05').

Descriptive statistics should include a clearly labelled measure of centre (such as the mean or the median), and a clearly labelled measure of variability (such as standard deviation or range). Ranges are more appropriate than standard deviations or standard errors for small data sets. Standard error or confidence interval is appropriate to compare data to a control. Graphs must include clearly labelled error bars for cases where more than two independent experiments have been performed (error bars for replicate samples are less useful). Authors must state whether a number that follows the ± sign is a standard error (s.e.m.) or a standard deviation (s.d.) Figure legends should contain a basic description of n, P and the test applied, and the Methods should contain further discussion of statistical methodology.

Since for complex biological experiments the number of independent repeats of a measurement often has to be limited for practical reasons, statistical measures with a very small n are commonplace. However, statistical measures applied to too small a sample size are not significant and they can suggest a false level of significance. We recommend that the actual individual data from each experiment should be plotted if n < 5, alongside an error bar. In cases where n is small, a justification for the use of the statistical test employed has to be provided. Presenting a single 'typical result' of n experiments is sometimes unavoidable, but should be accompanied by an indication of the variability of data between independent experiments. If n is not based on independent experiments (that is, n merely represents replicates of a measurement), statistics may still be useful, but a detailed description of the repeated measurement is required. For more information on the appropriate use of standard deviation, standard error, and confidence intervals please refer to Cumming et al (2007).

Authors must justify the use of a particular test and explain whether their data conform to the assumptions of the tests.

Tables

Tables should be typed on separate sheets and numbered consecutively. Tables should be self-explanatory and include a brief descriptive title. Footnotes to tables indicated by lower-case superscript letters are acceptable, but they should not include extensive experimental detail.

References

Only articles that have been published or that are accepted for publication at a named publication should be cited in the reference list. In the text of the manuscript, a reference should be cited by author and year of publication; no more than two authors may be cited per reference; 'et al' should be used if there are more than two authors (i.e. Smith & Jones, 2003; Smith et al, 2000). In the reference list, citations should be listed in alphabetical order and then chronologically, with the authors' surnames and initials inverted; where there are more than 10 authors on a paper, the first 10 will be listed, followed by 'et al.'. Publications by the same author(s) in the same year should be identified with a, b, c after the year of publication. The name of each journal should be abbreviated according to Index Medicus. References should therefore be listed as follows:

Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL, Shore RE (2002) Aspirin and lung cancer in women. Br J Cancer 87: 49-53

Book chapters and books can be cited in the following way:

Price SR, Oubridge C, Varani G, Nagai K (1998) Preparation of RNA-protein complexes for X-ray crystallography and NMR. In RNA-Protein Interaction: Practical Approach, Smith C (ed) pp 37-74. Oxford University Press, Oxford, UK

Sambrook J, Fritsch E & Maniatis T (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbour Press, Cold Spring Harbour, New York, USA

Papers accepted for publication must be cited with the corresponding author's permission and should include title and all author names (or initials if any of the authors are co-authors of the present contribution), as well as either the DOI, if available, or the term 'in press', as follows:

Bianchi F, Nicassio F, Marzi M, Belloni E, Dall'Olio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G, Di Fiore PP (2011) A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med DOI: 10.1002/emmm.201100155

Links to online resources and websites should be cited in the text only, and should be available long-term (e.g. permalinks or DOI wherever possible). URLs should not appear in the reference list.

Please download the Endnote Styles to format your manuscript at http://www.endnote.com/support/enstyles.asp.

Expanded View (replaces Supporting Information)

[Note: authors do NOT need to reformat their manuscript at first submission. The guidelines below are to be followed when submitting a revision.]

All data and information that are essential to support the scientific arguments made in the paper should be presented in figures that will be included in the main paper. Figures, tables or text sections that are not required by the general reader to understand the principle findings of the paper and that would disrupt the flow of paper should be submitted as 'Expanded View', which will be displayed in collapsible form and will replace Supporting Information. Please refer to each Expanded View item in the body of the text or the figure legends.

Expanded View Figures, tables or text represent an integral part of the published paper and benefit from the same peer-review and editorial production process as the other sections of the paper. Please note the Expanded View items are restricted to information essential to support the scientific arguments made in the paper. Peripheral, tangential or further reaching data and information should not be presented. Reference to 'data not shown' is discouraged'.

Expanded View items (Figures, Tables, Text) are displayed inline in the HTML version of the paper and are individually expandable/collapsible [note: currently files are linked to for download but full HTML rendering will come in the near future].

The article should be self-explanatory without the Expanded View sections. The scope of Expanded View sections should therefore be limited to the following categories:

  • controls and results from technical optimization experiments
  • replication or confirmation of previous results
  • negative results
  • extended methods and detailed protocols
  • mathematical demonstrations, algorithms, computer code and models
  • datasets

Note that controls and replicates to directly support the data presented in a figure should be supplied as 'Source Data' file linked to the relevant figure.

All Expanded View items should be cited in the text as "Figure E1", "Figure E2", Table E1", "Table E2", etc..., throughout the text.

Every Expanded View item should be accompanied by a legend that explains the content of the item. Expanded View legends should simply be included in the main manuscript file after the legends to the Figures and use the conventional format:

  • "Figure E1. Title of the item. Explanatory legend."

Each Expanded View item should in principle be supplied as an individual file. If this is not possible due to the nature of the information provided in Expanded View and the way it needs to be presented, a single PDF file (including a Table of Contents) can also be provided in exceptional cases and in agreement with the editors.

The following formats are accepted:

  • Expanded View Figure: jpg, gif, tiff, eps, pdf
  • Expanded View Tables (less than 50 rows): Word, Excel
  • Expanded View Text: Word, LaTeX
  • Expanded View Datasets and large tables (more than 50 rows): Excel, tab-delimited text, comma-separated values (csv), XML
  • Expanded View Code and Models: plain text, XML, ZIP compressed archives (including a README text file at the top level to detail the content and nature of each file included in the archive)
  • Expanded View Movie: mpeg, mov, avi

For the PDF version of the article, all displayable Expanded View items (Figures, Text and small tables) are automatically converted into PDF format and appended to the end of the article as part of a single downloadable 'PDF+' file. Files marked 'PDF' display the paper without Expandable View Items.

DATA DEPOSITION

Large-scale datasets, sequences, atomic coordinates and computational models should be deposited in one of the relevant public databases prior to submission (provided private access is available at the database) and authors should include accession codes in the Materials and Methods section. The suggested wording for referring to accession identifiers in a manuscript is the following: "The [protein interaction | microarray | mass spectrometry | protein structure] data from this publication have been submitted to the [name of the database] database [URL] and assigned the identifier [accession | permalink | hashtag]." If necessary, please include in the manuscript the relevant information (username and password) for confidential access by peer-reviewers.

Data for which no suitable public database exists should be included, if possible, as dataset files as part of the Expanded View. In cases where data cannot be confidentially deposited in a public database, and is too large to be included as part of the Expanded View, please contact the editorial office for advice on how to make these data available for refereeing purposes.

Functional genomics data

Microarray and sequencing-based functional genomics data should be deposited in the ArrayExpress (http://www.ebi.ac.uk/arrayexpress/), GEO (http://www.ncbi.nlm.nih.gov/geo/) or CIBEX (http://cibex.nig.ac.jp/index.jsp) databases in compliance to the MIAME (http://www.mged.org/Workgroups/MIAME/miame.html) standards and the MINSEQE (http://www.mged.org/minseqe/) draft proposal.

Proteomics and molecular interactions

Mass spectrometry datasets should be deposited in a machine-readable format (e.g. mzML if possible) in one of the major public database, for example Pride (http://www.ebi.ac.uk/pride/), PeptideAtlas (http://www.peptideatlas.org), or the Proteome Commons Tranche repository (https://proteomecommons.org/tranche/) and authors should follow the MIAPE recommendations (http://www.psidev.info/index.php?q=node/91)

Molecular interaction data should be deposited with a member of the International Molecular Exchange Consortium (IMEx, http://www.imexconsortium.org) prior to submission of the manuscript. Authors should follow the MIMIx recommendations (http://www.psidev.info/index.php?q=node/278).

Sequence data

Nucleotide sequence data should be submitted to an International Nucleotide Sequence Database Collaboration member: GenBank (http://www.ncbi.nlm.nih.gov/genbank/), EMBL Nucleotide Sequence Database (http://www.ebi.ac.uk/embl/) or DDBJ (http://www.ddbj.nig.ac.jp/).

Human clinical and genomic datasets

EMBO Molecular Medicine encourages authors to provide access to genotype and clinical data with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-controlled repositories such as dbGAP (http://www.ncbi.nlm.nih.gov/gap) or EGA (http://www.ebi.ac.uk/ega). Simple genetic polymorphisms should be submitted to dbSNP (http://www.ncbi.nlm.nih.gov/SNP/).

Structural data

EMBO Molecular Medicine accepts and follows the recommendations of the International Union of Crystallography (IUCr), with regard to the deposition and release of macromolecular structural data. These guidelines are set out in the article by the IUCr Commission on Biological Macromolecules in Acta Crystallographica (2000), D56, 2. In summary, they state that all publications must be accompanied by deposition of both the atomic coordinates and the structure-factor amplitudes in the appropriate database (PDB or NDB). In the case of low-resolution structures for which only a chain trace is reported, a set of C alpha positions and structure-factor amplitudes may be sufficient.

For NMR structures, data deposited should include resonance assignments, and all restraints used in structure determination (NOEs, spin-spin coupling constants, amide exchange rates, etc) and the derived atomic coordinates for both an individual structure and for a family of acceptable structures.

Structures of biological macromolecules solved by electron microscopy must be submitted to the EMDB database at http://www.ebi.ac.uk/msd/Deposition.html. For a brief description of the database, see Tagari et al. (2002) Trends Biochem Sci 27:589.

SUBMISSION

Presubmission enquiries

If you have already prepared a manuscript, please submit this via our online system as an article, rather than sending a presubmission enquiry. This allows the editors to make a more informed decision as to whether or not the manuscript is potentially appropriate for the journal.

Presubmissions can nevertheless be submitted to enquire whether a manuscript in preparation is likely to be of interest to the journal. Presubmission enquiries should be submitted via online submission system (http://embomolmed.msubmit.net/cgi-bin/main.plex) or by e-mail (contact@embomolmed.org) and should minimally include a list of all authors, a cover letter and an abstract.

Appeals on presubmission enquiries are not entertained, but we are open to considering a full manuscript in these cases.

How to submit

We use an online manuscript submission and tracking system: http://embomolmed.msubmit.net/cgi-bin/main.plex

In order to submit, you must have registered for an account. After this, please consult the following instructions for submission via our secure server. Please be sure that your browser is set to accept cookies. Our tracking system requires cookies for proper operation. Please refrain from submitting your manuscript by e-mail attachment.

For original submissions, you will need to upload a cover letter, a Word file of the text of the manuscript (including figure legends), and a PDF file containing all the figures. Alternatively, individual figure files can be uploaded separately but please note that this can be more time-consuming than a PDF submission. Additional files for the Expanded View can also be uploaded when applicable (please refer to the section 'Expanded View' above).

Once you have submitted your files and the conversion is in progress, it can take up to 30 minutes before the PDF, created in the conversion process, is ready for approval. Please contact the editorial office [contact@embomolmed.org] if the conversion engine takes longer than this. It is important to check the quality of the figures in the converted PDF before approving the submission. Please remember that your manuscript will not be submitted until you have approved the converted files.

To avoid any unnecessary delays, please refer to the most current electronic formatting guidelines when preparing your manuscript for submission. Authors using computer systems with non-Western type encoding are strongly encouraged to eliminate all occurrences of non-standard fonts in both the manuscript and the figures. We suggest using only the fonts Times, Symbol, Courier and Helvetica.

We will acknowledge receipt of a submitted manuscript by e-mail as soon as the quality check (appropriate manuscript format and image quality) has been completed. All further correspondence will also be by e-mail. Please ensure that your servers are set up to allow e-mails from the journal, and contact us if you do not receive an acknowledgement e-mail within a few days of submission.

Manuscript status

You can check the status of your manuscript at any time in the review process by:
1. Accessing the system with your password or link sent to you in the acknowledgement e-mail.
2. Clicking on the link represented by your manuscript tracking number and abbreviated title.
3. Clicking on the "Check Status" link at the bottom of the displayed page.

This procedure will display tracking information about where your manuscript is in the submission/peer review process. Please feel free to contact the editorial office [contact@embomolmed.org] with status queries.

Submission of revisions

When a manuscript is returned to authors for revision, the revised version should be submitted within three months of the authors' receipt of the referee reports, unless another date is specified in the decision letter. Please contact the editor by the deadline in cases where extra time is required for revision. Additional time may be granted upon request at the editors' discretion, assuming the conceptual advance of the study stands (with regard to the current literature). As a matter of policy, we do not consider any competing manuscripts published during the specified revision period as negatively impacting on the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed.

Only a single round of revision is generally permitted.

The initial decision letter on the original version of the manuscript provides a URL that should be used for submission of revised manuscripts. Please do not upload revisions as new submissions.

Revisions should be accompanied by a point-by-point response to the referees' comments as well as the editorial decision letter, in PDF or Word format. To facilitate the re-evaluation, we encourage authors to intercalate their response with the referee comments.

Revisions must also be accompanied by a completed author checklist. Right click to download and complete the author checklist here.

FOR ACCEPTANCE AND PUBLICATION

Before acceptance and transfer to our publishers, manuscripts will be checked for appropriate formatting and image processing, and for plagiarism. We cannot proceed to acceptance until data are available in public databases when required; see above for details.

Authors may provide a high-resolution file of a striking image related to their study, which may be selected and used as a cover image for the online issue.

Speed of publication

The journal aims for rapid publication of papers using an advance online publication named 'Early View' to expedite the process. Once a manuscript is accepted, a properly copy-edited and formatted version will be published as 'Early View' after payment of the article publication charge and after the proofs have been corrected by the authors. Please help the editors and publisher avoid delays by providing current e-mail address(es), telephone and fax numbers at which author(s) can be contacted.

Proofs

The corresponding author will be sent an e-mail with a link to download their proof. The PDF should be clearly annotated for necessary corrections and then returned by e-mail to wileyvch.j@thomsondigital.com. It is the authors' responsibility to check that the final proof is accurate. In the interests of speed, corrections should be returned within 48 hours. Essential changes of an extensive nature may be made only by insertion of a 'Note added in proof', and only with the approval of the editors. A charge will be made to authors who insist on extensive amendment within the text at the page proof stage. Excessive alterations may delay publication of the article.

Open access and charges

EMBO Molecular Medicine levies an article publication charge of 3,000 EUROS (3,900 USD) per article accepted for publication (Research Articles, Reports, non-commissioned Reviews and Perspectives). There are no additional costs (such as page charges or submission charges).

Commissioned articles are free of any publication charges.

Upon acceptance, the corresponding author will receive instructions by email for completing the relevant license forms and payments. We will automatically waive or discount charges for corresponding authors working in countries covered by the Research4Life Initiative (see the Wiley Open Access Waiver Country List). In exceptional circumstances charges may be reduced for authors that can provide evidence that they are unable to pay the fees.

Processing of an accepted manuscript for publication can only proceed once the charge payment form and licence to publish have been returned.

Authors who receive funding from an agency or institution with a Wiley Open Access Account do not pay directly. The charge is paid by the institution or funder. Authors whose institutions have paid the Wiley Open Access partner fee are eligible for a discount on the publication charge and on acceptance a discounted fee is payable by the author. Please see additional details on the payment form.

EMBO Molecular Medicine articles are freely accessible to all via the Internet and are also deposited immediately upon publication, without embargo, to the Open Access repository PubMed Central.

Copyright on any article published by EMBO Molecular Medicine is retained by the author(s).

EMBO Molecular Medicine articles are published under the Creative Commons Attribution CC BY 4.0 License. This license permits users to access, download, copy, display and redistribute Molecular Systems Biology articles, as well as adapt, translate, text- and data-mine the content subject to the following conditions:

  • The authors' moral rights are not compromised. These rights include the right of "paternity" (also known as "attribution" - the right for the author to be identified as such) and "integrity" (the right for the author not to have the work altered in such a way that the author's reputation or integrity may be impugned).
  • If article content is copied, downloaded or otherwise reused, a link to the appropriate bibliographic citation (authors, journal, article title, volume, issue, page numbers, DOI and the link to the definitive published version) should be maintained. Copyright notices and disclaimers must not be deleted.
  • Where content in the article is identified as belonging to a third party, it is the obligation of the user to ensure that any reuse complies with the copyright policies of the owner of that content.

Please note that any file labeled “Source Data”, “Dataset” or “Resource” is released under a Creative Commons CC0 1.0 Universal Licence. This waiver removes legal barriers to the re-use and mining of research data. According to standard scholarly practice, it is recommended to provide appropriate citation and attribution whenever technically possible.

Offprints

Offprint order forms will be sent with the proofs and should be completed and returned to the publisher as soon as possible.

Digital object identifier

The journal assigns a unique digital object identifier (DOI) to every article it publishes. The DOI initiative is an international effort for electronic content identification and is guided by the International DOI Foundation composed primarily of academic publishers and societies. The DOI appears on the title page of the article. It is assigned after the article has been accepted for publication and persists throughout the lifetime of the article. It is important to include the article's DOI in the reference, as volume and page information is not always available for articles published online.

HELP AND CONTACT

If you need additional help during submission, you can click on the help signs (icon) spread throughout the system. A help dialogue will pop up with context sensitive help. Should further assistance be required, then please contact MTS help. For questions regarding our policies and guidelines, please contact the EMBO Molecular Medicine editorial office (contact@embomolmed.org).